BioSpace News Archive

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announces that it has appointed Michael L. Derby to its Board of Directors.

Delcath Systems, Inc. today reported business highlights and financial results for the fourth quarter and full-year ended December 31, 2021.

Timber Pharmaceuticals, Inc. announced a late-breaking presentation of a sub-analysis of the Phase 2b CONTROL study that evaluated TMB-001, a topical isotretinoin formulated using the company’s patented IPEG™ delivery system, at the American Academy of Dermatology 2022 Annual Meeting being held in Boston, MA, from March 25-29.

Heat Biologics,Inc., a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, unveiled enhanced allogeneic cell therapy manufacturing capabilities through its Scorpion Biological Services subsidiary.

Dermavant Sciences announced Phase 3 PSOARING 3 long-term extension study results demonstrating durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily for the treatment of plaque psoriasis in adults.

Sky Medical Technology Ltd (Sky) has today announced it has achieved further U.S. Food and Drug Administration (FDA) 510(k) clearance to market the new (W3) geko™ device variant, for increasing microcirculatory blood flow in lower limb soft tissue of patients with venous insufficiency and/or ischemia.

NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, announced it has received proceeds of approximately $4 million from the exercise of warrants priced at $6 per share.

CUTERA, INC. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of dermatology solutions, today announced the U.S. Food and Drug Administration’s 510(k) clearance of AviClear, the first and only energy-based device to receive this designation for the treatment of mild, moderate, and severe acne.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), today announced that Joseph Payne, President and CEO of Arcturus Therapeutics, will participate in a panel discussion titled “RNA Therapeutics in Rare Diseases” at the Cantor Fitzgerald Virtual rare Disease Summit on Barclays Global Healthcare Conference.

TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced changes to its Board of Directors.